Advertisement

What can psychological treatments say about causes in schizophrenia?

  • Shôn W. Lewis
  • Richard J. Drake
Conference paper

Abstract

There is increasing interest in the possibility that specific and specifiable psychological treatments can be effective in reducing the symptoms of schizophrenia. What is the evidence for this and what might the amenability of core symptoms to psychological intervention tell us about mechanisms in the pathogenesis and maintenance of psychotic symptoms in schizophrenia?

Keywords

Psychotic Symptom Psychological Treatment Cognitive Behaviour Therapy Chronic Schizophrenia Street Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Agrawal N, Aleman A, Morgan KD, David AS (2003) Insight in psychosis and neuropsychological function: a meta-analysis. Schizophrenia Research 60(1)(Suppl1): 120CrossRefGoogle Scholar
  2. Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O’Brien R, Schofield N, McGovern J (2001) Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. Am J Psychiatry 158(10):1706–1713PubMedCrossRefGoogle Scholar
  3. Bilder RM, Volavka J, ál Czobor P, Malhotra AK, Kennedy JL, Ni X, Goldman RS, Hoptman MJ, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Kunz M, Chakos M, Cooper TB, Lieberman JA (2003) Neurocognitive correlates of the COMT Va1158Met polymorphism in chronic schizophrenia. Biological Psychiatry 52(7): 701–707CrossRefGoogle Scholar
  4. Butzlaff RL, Hooley JM (1998) Expressed emotion and psychiatric relapse: a meta-analysis. Arch Gen Psychiatry 55(6):547–552PubMedCrossRefGoogle Scholar
  5. Drake RJ, Lewis SW (2003) Insight and neurocognition in acute schizophrenia and related disorders. Schizophrenia Research 62(1/2):165–173PubMedCrossRefGoogle Scholar
  6. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001) Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98(12):6917–6922PubMedCrossRefGoogle Scholar
  7. Frith CD (1992) The cognitive neuropsychology of schizophrenia. LEA press, Hove, UKGoogle Scholar
  8. Garety P, Kuipers E, Fowler D, Freeman D, Bebbington P (2001) A cognitive model of the positive symptoms of psychosis. Psychological Medicine 31:189–195PubMedCrossRefGoogle Scholar
  9. Haddock G, Barrowclough C, Tarrier N, Moring J, O’Brien R, Schofield N, Quinn J, Palmer S, Davies L, Lowens I, McGovern J, Lewis S (2003) Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse. 18-month outcomes of a randomised controlled trial. Br J Psychiatry 183:418–426PubMedCrossRefGoogle Scholar
  10. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G (1993) Wisconsin Card Sorting Test Manual (Psychological Assessment Resources, Odessa, FL)Google Scholar
  11. Hemsley DR (1993) A simple (or simplistic?) cognitive model for schizophrenia. Behaviour Research and Therapy 31:633–645PubMedCrossRefGoogle Scholar
  12. Kay SR, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13:507–518CrossRefGoogle Scholar
  13. Kemp R, Hayward P, Applethwaite G, Everritt B, David A (1996) Compliance therapy in psychotic patients: randomised controlled trial. BMJ 312:345–349PubMedCrossRefGoogle Scholar
  14. Kemp R, Kirov G, Everitt B, Hayward P, David A (1998) Randomised controlled trial of compliance therapy: 18-month follow-up. British Journal of Psychiatry 172:413–419PubMedCrossRefGoogle Scholar
  15. Koren D, Seidman LJ, Poyurovski M, Viksman P, Balush V, Goldsmith M, Klein E (2003) Insight in first-episode schizophrenia: a metacognitive neuropsychological study. Schizophrenia Research 60(1)(Suppl 1):173–174CrossRefGoogle Scholar
  16. Kuipers E, Garety P, Fowler D, Dunn G, Bebbington P, Freeman D, Hadley C (1997) The London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I. Effects of the treatment phase. British Journal of Psychiatry 171:319–327PubMedCrossRefGoogle Scholar
  17. Laroi F, Fannemel M, Ronneberg U, Flekkoy K, Opjordsmoen S, Dullerud R, Haakonsen M (2000) Unawareness of illness in chronic schizophrenia and its relationship to structural brain measures and neuropsychological tests. Psychiatry Res 100(1): 49–58PubMedCrossRefGoogle Scholar
  18. Lewis S, Tarrier N, Haddock G, Bentall R, Kinderman P, Kingdon D, Siddle R, Drake R, Everitt J, Leadley K, Benn A, Grazebrook K, Haley C, Akhtar S, Davies L, Palmer S, Faragher B, Dunn G (2002) Randomised controlled trial of cognitive-behavioural therapy in early schizophrenia: acute-phase outcomes. British Journal of Psychiatry 181 (Suppl 43):91–97CrossRefGoogle Scholar
  19. Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and the course of re-cent-onset schizophrenic disorders. Archives of General Psychiatry 51(4):273–279PubMedCrossRefGoogle Scholar
  20. Lysaker PH, Bell MD, Bryson G, Kaplan E (1998) Neurocognitive function and insight in schizophrenia: support for an association with impairments in executive function but not with impairments in global function. Acta Psychiatr Scand 97(4):297–301PubMedCrossRefGoogle Scholar
  21. Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D (2002) A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 159:652–654PubMedCrossRefGoogle Scholar
  22. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR (2003) Catechol 0-methyltransferase va1158-met genotype and individual variation in the brain response to amphetamine Proc Natl Acad Sci USA 13; 100(10):6186–6191CrossRefGoogle Scholar
  23. McGorry PD, Yung AR, Phillips LJ et al (2002) Randomised controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 59: 921–928CrossRefGoogle Scholar
  24. Morrison AP, Bentall RP, French P, Kilcommons A, Walford L, Lewis SW (2002) A randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high risk individuals: study design and interim analysis of transition rate and psychological risk factors. British Journal of Psychiatry 181 (Suppl 43):78–84CrossRefGoogle Scholar
  25. Mueser KT, Berenbaum H (1990) Psychodynamic treatment of schizophrenia: is there a future? Psychol Med 20:253–262PubMedCrossRefGoogle Scholar
  26. Pharoah FM, Mari JJ, Streiner D (2000) Family intervention for schizophrenia. Cochrane Database Syst Rev (2):CD000088PubMedGoogle Scholar
  27. Rossell SL, Coakes J, Shapleske J, Woodruff PW, David AS (2003) Insight: its relationship with cognitive function, brain volume and symptoms in schizophrenia. Psychol Med 3(1):111–119Google Scholar
  28. Sellwood W, Barrowclough C, Tarrier N, Quinn J, Mainwaring J, Lewis SW (2001) Needs-based cognitive-behavioural family intervention for carers of patients suffering from schizophrenia: 12-month follow-up. Acta Psychiatr Scand 104(5):346–355PubMedCrossRefGoogle Scholar
  29. Sensky T, Turkington T, Kingdon D, Scott JL, Scott J, Siddle R, O’Carroll M, Barnes TRE (2000) A randomised, controlled trial of cognitive behaviour therapy for persistent positive symptoms in schizophrenia resistant to medication. Archives of General Psychiatry 57:165–173PubMedCrossRefGoogle Scholar
  30. Tarrier N, Sharpe L, Beckett R, Harwood S, Baker A, Yusopoff L (1993) A trial of two cognitive behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients. II. Treatment-specific changes in coping and problem-solving skills. Soc Psychiatry Psychiatr Epidemiol 28(1):5–10PubMedCrossRefGoogle Scholar
  31. Tarrier N, Yusopoff L, Kinney C et al (1998) Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. BMJ 317: 303–307PubMedCrossRefGoogle Scholar
  32. Viksman P, Poyurovsky M, Balush V, Levy A, Fuchs E, Eytan Y, Burzstein C, Goldsmith M, Koren D (2002) Metacognition in first episode schizophrenia: its relationship to theory of mind and executive functioning. Schizophrenia Research 53 (3):137Google Scholar
  33. Wahlbeck K, Cheine M, Essali MA (2000) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev (2):CD000059PubMedGoogle Scholar
  34. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman KF, Goldberg TE (2001) Neurobiology of schizophrenia and the role of atypical antipsychotics. Biol Psychiatry 50:825–844PubMedCrossRefGoogle Scholar
  35. Wykes T, Reeder C, Corner J, Williams C, Everitt B (1999) The effects of neurocognitive remediation on executive processing in patients with schizophrenia. Schizophrenia Bulletin 25(2):291–307PubMedCrossRefGoogle Scholar
  36. Wykes T, Reeder C, Williams C et al (2002) Are the effects of cognitive remediation ther-apy (CRT) durable? Results from an exploratory trial. Schizophrenia Res (in press)Google Scholar
  37. Yung A, Phillips LJ, McGorry PD et al (1998) A step towards indicated prevention ofschizophrenia. British Journal of Psychiatry 172 (Suppl 33):14–20Google Scholar
  38. Sensky T, Turkington T, Kingdon D, Scott JL, Scott J, Siddle R, O’Carroll M, Barnes TRE (2000) A randomised, controlled trial of cognitive behaviour therapy for persistent positive symptoms in schizophrenia resistant to medication. Archives of General Psychiatry 57:165–173PubMedCrossRefGoogle Scholar
  39. Young DA, Zakzanis KK, Bailey C, Davila R, Griese J, Sartory G, Thom A (1998) Further parameters of insight and neuropsychological deficit in schizophrenia and other chronic mental disease. J New Ment Dis 186(1):44–50CrossRefGoogle Scholar
  40. Yung A, Phillips LJ, McGorry PD et al (1998) A step towards indicated prevention of schizophrenia. British Journal of Psychiatry 172 (Suppl 33):14–20Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Shôn W. Lewis
    • 1
  • Richard J. Drake
    • 1
  1. 1.School of Psychiatry and Behavioural SciencesUniversity of ManchesterManchesterUK

Personalised recommendations